文献速递呼吸衰竭与机械通气儿科与产科急症

双水平气道正压通气联合持续沙丁胺醇治疗儿童哮喘急性发作:一项随机临床试验

Bilevel Positive Airway Pressure and Continuous Albuterol for Pediatric Asthma Exacerbations: A Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2026-08-03
一句话结论在急诊对中度儿童哮喘急性发作早期使用BPAP,未能显著缩短持续β受体激动剂治疗时间(8.3 vs 8.7小时,差异无统计学意义)。

这项双盲随机临床试验在单中心四级转诊儿童急诊开展,纳入5至17岁、儿童呼吸评估量表至少4分(中度)并接受持续沙丁胺醇治疗的急性哮喘发作患儿,随机分为BPAP组或假BPAP组治疗4小时。主要终点为持续沙丁胺醇治疗时间。50%期中分析时,BPAP组平均8.3小时 vs 对照组8.7小时(平均差-0.5小时,95%CI -5.0至4.1,P=0.84),研究因达到无效性界限而提前终止。两组均未观察到死亡、有创机械通气、漏气综合征或吸入性肺炎。作者认为需在更重度哮喘队列中开展开放性研究。

要点

  • 在急诊对5至17岁、儿童呼吸评估量表至少4分的中度哮喘发作患儿早期使用BPAP,持续沙丁胺醇治疗时间BPAP组8.3小时 vs 假BPAP组8.7小时(平均差-0.5小时,95%CI -5.0至4.1,P=0.84)。
  • 研究在50%期中分析时因达到预设无效性界限而提前终止,未观察到BPAP缩短持续β受体激动剂治疗时间的临床显著获益。
  • 两组均未出现死亡、有创机械通气、漏气综合征或吸入性肺炎。
  • 作者结论认为,需在更重度哮喘队列中开展开放性研究以更好指导临床实践。

适用人群与场景

  • 5至17岁儿童,因急性哮喘发作就诊于单中心四级转诊儿童急诊,儿童呼吸评估量表至少4分(中度严重度),并处方持续沙丁胺醇治疗。

诊断标准与关键阈值

  • 儿童呼吸评估量表至少4分定义为中度严重度,为纳入标准之一。

处置流程与药物剂量

  • 纳入患儿随机接受BPAP或假BPAP(提供最小压力)治疗4小时,两组均接受持续沙丁胺醇治疗。
  • 研究为双盲设计,医疗从业者与参与者均不知晓分组。

研究设计与关键结果

  • 双盲随机临床试验,单中心,纳入66例患儿(中位年龄10.2岁,IQR 6.8-13.2;男性35例,53.0%),平均(SD)儿童呼吸评估量表5.2(1.9)。
  • 50%期中分析时,BPAP组持续沙丁胺醇平均(SD)8.3(8.5)小时 vs 对照组8.7(10.0)小时,平均差-0.5小时(95%CI -5.0至4.1,P=0.84),未达统计学显著。
  • 研究因在50%期中分析达到预设无效性界限而终止。
  • 两组均未观察到死亡、有创机械通气、漏气综合征或吸入性肺炎。

证据类型、等级与局限

  • 证据类型:双盲随机临床试验。
  • 研究因无效性提前终止。
  • 局限:作者指出需在更重度哮喘队列中开展开放性研究以更好指导临床实践。

对床旁实践的改变

  • 对于5至17岁中度儿童哮喘急性发作(儿童呼吸评估量表至少4分)并接受持续沙丁胺醇治疗的患儿,急诊早期使用BPAP未显示可缩短持续β受体激动剂治疗时间。
  • 作者认为,需在更重度哮喘队列中开展开放性研究以更好指导临床实践。

指南或共识出处

  • 临床试验注册号:ClinicalTrials.gov NCT05848115。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: A substantial knowledge gap remains in understanding the specific role bilevel positive airway pressure (BPAP) in the emergency department (ED) for acute pediatric asthma exacerbations.

OBJECTIVE: To examine whether the early application of BPAP in the ED for acute pediatric asthma exacerbations reduces duration of critical care management time.

DESIGN, SETTING, AND PARTICIPANTS: This double-blind randomized clinical trial enrolled children between 5 and 17 years of age presenting to a single-center, quaternary, referral pediatric ED with an acute asthma exacerbation, a pediatric respiratory assessment measure of at least 4 (moderate severity), and prescribed continuous albuterol therapy between June 1, 2023, and May 31, 2025.

INTERVENTION: Participants were randomized to either the intervention arm (BPAP) or control arm (sham BPAP, which delivers minimal pressure) for 4 hours. Neither the health care practitioners nor participants were aware of study arm allocation.

MAIN OUTCOME AND MEASURES: The primary outcome measure was duration of continuous albuterol therapy. A sequential design with a planned interim analysis for futility and superiority was used, and a t test compared mean duration of continuous β-agonist therapy under an intention-to-treat approach.

RESULTS: Sixty-six study participants (median [IQR] age, 10.2 [6.8-13.2] years; 35 [53.0%] male; 1 [1.5%] American Indian or Alaskan, 1 [1.5%] Asian, 21 [31.8%] Black or African American, 21 [31.8%] White, and 22 [33.3%] other race) were included in the primary analysis, with a mean (SD) pediatric respiratory assessment measure of 5.2 (1.9), indicating moderate disease. At the 50% interim analysis, participants in the BPAP study arm received a mean (SD) of 8.3 (8.5) hours of continuous albuterol vs 8.7 (10.0) hours in the control group (mean difference, -0.5 hours; 95% CI, -5.0 to 4.1 hours; P = .84). The study was stopped due to meeting a priori bounds for futility at the 50% interim analysis. No deaths, invasive mechanical ventilation, air leak syndrome, or aspiration pneumonia were observed in either study arm.

CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of early initiation of BPAP in the ED, no clinically significant decrease in the duration of continuous β-agonist therapy in pediatric patients presenting with moderate asthma exacerbations was observed. Additional open-label studies in a more severe asthma cohort are required to better inform clinical practice.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05848115.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Wilson PT, Tanverdi M, Brinton JT, et al. Bilevel Positive Airway Pressure and Continuous Albuterol for Pediatric Asthma Exacerbations: A Randomized Clinical Trial. JAMA Netw Open. 2026. PMID: 42646841. doi:10.1001/jamanetworkopen.2026.30627

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。